Abivax
ABVX
254 hedge funds and large institutions have $5.53B invested in Abivax in 2026 Q1 according to their latest regulatory filings, with 53 funds opening new positions, 111 increasing their positions, 75 reducing their positions, and 43 closing their positions.
63% more call options, than puts
Call options by funds: $233M | Put options by funds: $142M
48% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 75
23% more first-time investments, than exits
New positions opened: 53 | Existing positions closed: 43
3% more funds holding
Funds holding: 247 → 254 (+7)
9.05% less ownership
Funds ownership: 72.25% → 63.2% (-9%)
18% less funds holding in top 10
Funds holding in top 10: 34 → 28 (-6)
27% less capital invested
Capital invested by funds: $7.61B → $5.53B (-$2.08B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
Helikon Investments
London,
United Kingdom
|
+$120M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
+$37M |
| 3 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$34.3M |
| 4 |
EP
Eversept Partners
New York
|
+$32.7M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$210M |
| 2 |
Morgan Stanley
New York
|
-$171M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$103M |
| 4 |
PBA
Paradigm Biocapital Advisors
New York
|
-$76.3M |
| 5 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$74.6M |
ABVX Hedge Fund Activity: Q1 2026 in Review
254 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Abivax (ABVX) for Q1 2026, worth a combined $5.53B — down 27% from $7.61B a quarter earlier.
Buyers outnumbered sellers: 53 funds opened new ABVX positions and 43 closed out — a net gain of 10 holders — while 111 added to existing stakes and 75 trimmed.
The largest buyer was Helikon Investments, opening a new position worth an estimated $120M. The largest seller was Point72 Asset Management, cutting an estimated $210M.
- 254 institutional investors held Abivax (ABVX) as of Q1 2026, up from 247 in Q4 2025.
- Funds reported $5.53B of Abivax stock for Q1 2026, down 27% quarter-over-quarter.
- 53 funds opened new Abivax positions in Q1 2026 and 43 closed out, a net change of +10 holders.
- The largest Abivax buyer in Q1 2026 was Helikon Investments, an estimated $120M added.
- The largest Abivax seller in Q1 2026 was Point72 Asset Management, an estimated $210M sold.
Based on aggregated 13F filings for Q1 2026.